Charcot-Marie-Tooth (CMT) – Market Outlook, Forecast and Competitive Landscape report- 2019-2030

Indication name: Charcot-Marie-Tooth (CMT)

Charcot-Marie-Tooth (CMT) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Charcot-Marie-Tooth disease (CMT) is one of a group of disorders that cause damage to the peripheral nerves—the nerves that transmit information and signals from the brain and spinal cord to and from the rest of the body, as well as sensory information such as touch back to the spinal cord and brain. CMT is caused by mutations in genes that support or produce proteins involved in the structure and function of either the peripheral nerve axon or the myelin sheath. More than 40 genes have been identified in CMT, with each gene linked to one or more types of the disease. In addition, multiple genes can be linked to one type of CMT. More than half of all cases of CMT are caused by a duplication of the PMP22 gene on chromosome 17.

Classification-

There are different types of CMT disease such as; CMT1, CMT2, CMT3 (Dejerine-Sottas disease), CMT4, CMTX1 (also called CMT X, Type 1)

Epidemiology-

CMT is one of the most common inherited neurological disorders, affecting an estimated 148,000 individuals in the United States and > 3.2 million people worldwide.

Competitive landscape of Acromegaly includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Charcot-Marie-Tooth (CMT) 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Charcot-Marie-Tooth (CMT) market forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Charcot-Marie-Tooth (CMT) – Market Outlook, Forecast and Competitive Landscape report- 2019-2030

S. No Asset Company Partner Phase
1 PXT3003 Pharnext SA Tasly Pharmaceutical Group III
2 NT-3 Gene Therapy Nationwide Children’s Hospital Sarepta Therapeutics I/II
3 IFB-088 InFlectis BioScience N/A I
4 Engensis Helixmith Co., Ltd. Northland Status to confirm
5 CMT4J Disease Therapy Neurogene Inc. N/A Preclinical
6 Ricolinostat Bristol-Myers Squibb Company Regenacy Preclinical